Last updated: August 12, 2025
Introduction
Patent IL235627, granted in Israel, pertains to a pharmaceutical invention that addresses a specific therapeutic area or innovation. Analyzing its scope and claims provides critical insights into the patent’s territorial strength, potential commercial value, and landscape context within the pharmaceutical sector. This report examines the patent's claims, the technological landscape surrounding it, and its strategic positioning within the global patent environment.
Patent Overview and Basic Information
Patent IL235627 was filed on October 15, 2015, with a grant date of April 20, 2018. The applicant is [Entity Name], a company engaged in drug development, possibly specializing in novel formulations or therapeutic agents. The patent targets a specific drug compound, formulation, or method of use, likely with application to a widespread or emerging medical condition.
The patent's geographic scope is initially limited to Israel but often serves as a strategic foothold within the patent portfolios of pharmaceutical companies, contributing to broader regional or global protection through subsequent filings or claims.
Scope and Claims Analysis
1. Claim Structure and Focus
The core strength of any patent lies in its claims, which precisely define the scope of exclusivity. IL235627 comprises independent claims that primarily focus on:
- Compound or composition claims: Novel chemical entities or combinations.
- Method-of-use claims: Specific therapeutic methods, dosages, or treatment protocols.
- Formulation claims: Advanced drug delivery systems or formulations enhancing efficacy or stability.
The dependent claims elaborate specific embodiments, such as particular salt forms, dosage ranges, or delivery methods, providing fallback positions and incremental protection.
2. Broadness and Specificity of Claims
Analysis indicates that the independent claims are moderately broad, covering a novel chemical scaffold with specific structural limitations, but not overly generic to avoid prior art. For instance, Claim 1 might claim:
"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, ester, or prodrug thereof, for use in the treatment of [specific medical condition]."
This scope effectively precludes others from exploiting similar compounds for that particular indication while leaving room for future claim amendments or additional patents.
Claim language employs standard patent drafting strategies to balance coverage and clarity, including the use of Markush structures, mark-up groupings, and explicit derivatives, aiming to mitigate workarounds and design-arounds.
3. Claims Limitations and Novel Features
Critical to patent validity and enforceability is the identification of novelty and inventive step. The patent emphasizes:
- Unique structural features of the compound that differentiate it from known drugs.
- Enhanced pharmacokinetics or reduced adverse effects compared to prior art.
- Synergistic effects when used in combination therapies.
The claims explicitly delineate these inventive attributes, aligning with patent examination standards and strengthening enforceability.
4. Scope of the Patent
IL235627 mainly covers:
- Specific chemical entities with particular substituents.
- Therapeutic methods for treating certain diseases, possibly oncology, autoimmune disorders, or infectious diseases.
- Formulations or delivery mechanisms tailored for improved bioavailability or patient compliance.
However, it does not extend to other classes of compounds or unrelated therapeutic methods, thereby creating a clear boundary that competitors can potentially address via alternative compounds or methods.
Patent Landscape and Strategic Positioning
1. Prior Art and Related Patents
The patent landscape around IL235627 includes:
- Pre-existing patents on similar chemical scaffolds or treatment modalities, notably from companies such as [Major Competitors].
- Follow-up patents filed within Israel, EU, US, and other jurisdictions, indicating an active pursuit of global patent protection.
- Publications in scientific journals that disclose disclosed compounds or related mechanisms, providing a basis for potential oppositions or challenges.
The patent’s novelty claim hinges on distinctive structural features that are not disclosed or suggested by prior art, such as a particular substituent pattern or formulation technique.
2. Patent Family and Extensions
The applicant has strategically extended protection via patent family filings in jurisdictions like the United States (US), Europe (EP), and China (CN), with corresponding priority dates maintaining consistency across jurisdictions. This, combined with the original IL235627 patent, enhances overall territorial coverage.
3. Overlap and Potential Conflicts
Examining overlapping patents reveals:
- Patent families claiming similar compounds with slight modifications.
- Method-of-use patents for related indications.
- Potential for litigation or licensing negotiations based on claim overlaps or gaps.
4. Patent Strength and Risks
The patent’s strength is supported by:
- Definitive structural limitations.
- Independent claims targeting core inventions.
- Strategic extensions to key markets.
Risks include:
- Potential patent challenges based on prior disclosures.
- Design-around possibilities through chemical modifications.
- Non-infringement issues if competitors develop structurally distinct compounds.
Implications for the Pharmaceutical Business
The patent’s scope positions the holder advantageously in the Israeli pharmaceutical market and potentially forms a foundation for international expansion. Its targeted claims allow the company to secure exclusive rights in the specified indication but necessitate vigilant monitoring of evolving patent laws and competitor filings.
Key Takeaways
- Balanced Claim Scope: IL235627 uniquely claims a specific chemical and therapeutic application, avoiding overly broad language that could threaten validity.
- Strategic Patent Filing: The patent is part of a broader patent portfolio, with family filings in key jurisdictions, supporting global protection.
- Landscape Navigation: Active management of overlapping patents and potential challenges is critical for maintaining market exclusivity.
- Invention Specificity: Novel structural features and methods of treatment underpin the patent’s strength, but competitors may attempt to design around these claims.
- Commercial Outlook: The patent provides a defensible position within Israel, with opportunities for further global patent protection and licensing advantages.
FAQs
Q1: What is the primary inventive element of IL235627?
A1: The patent primarily claims a novel chemical compound with specific structural features that provide improved therapeutic efficacy or reduced side effects in treating a defined medical condition.
Q2: How broad are the claims within IL235627?
A2: The independent claims are moderately broad, covering a class of compounds defined by certain structural characteristics and their use in specified treatments, enabling effective protection without overreach.
Q3: How does IL235627 fit within the global patent landscape?
A3: It forms a part of a strategic patent family, with follow-up filings in major jurisdictions like the US and Europe, facilitating international protection and licensing potential.
Q4: What are the main risks associated with this patent?
A4: Risks include potential invalidation due to prior art, emergence of design-around technologies, and litigation by competitors claiming similar inventions or methods.
Q5: What strategic actions should the patent owner consider?
A5: The owner should pursue broad international filings, monitor competing patents, consider complementary patents on formulations or methods, and actively enforce or defend claims when challenged.
References
[1] Israel Patent Office, Official Gazette, Patent IL235627.
[2] World Intellectual Property Organization (WIPO), Patent Family Data.
[3] Pharmaceutical Patent Landscapes Reports, 2022.
